Business Context and Reporting Period
This Form 6-K filing by Immunocore Holdings Plc covers the month of September 2022, specifically dated September 9, 2022. The report details the execution of an Open Market Sale Agreement with Jefferies LLC to facilitate an at-the-market offering of American Depositary Shares (ADSs).
Key Financial Metrics
The filing does not provide specific revenue, profit, cash flow, margin, debt, or liquidity figures for the reporting period. The primary financial metric disclosed is the aggregate offering price of up to $250,000,000 for the potential sale of ADSs under the new Sales Agreement. The commission payable to the sales agent is up to 3.0% of the gross sales price.
Material Changes
The material change reported is the establishment of a new sales mechanism for equity financing. On September 9, 2022, the Company entered into an agreement allowing it to issue and sell ADSs from time to time through Jefferies LLC acting as a sales agent or principal. This offering is registered under the Company's automatic shelf registration statement on Form F-3ASR.
Guidance, Outlook, and Risks
The filing does not contain specific financial guidance or management commentary regarding future operational performance. The document notes that the Sales Agreement includes customary representations, warranties, and indemnification provisions. It also states that the agreement may be terminated by either party upon written notice. The filing explicitly states it does not constitute an offer to sell securities in jurisdictions where such an offer would be unlawful.
Investor Verification Checklist
- Verify the total number of ADSs sold and the actual proceeds generated under the Sales Agreement in subsequent filings.
- Review the full text of the Sales Agreement (Exhibit 1.1) for specific termination rights and conditions.
- Check the Prospectus Supplement (Exhibit 99.1) for the updated "Recent Developments" section regarding the Company's business.
- Monitor future Form 6-K or 20-F filings for actual cash flow impacts and dilution effects from the at-the-market offering.